NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoid-like molecules, today announced the release of its new investor deck.